Replies to post #73320 on Biotech Values

[go seek]

IDX899... any guesstimate on when P2 results?

Will IDIX be @ $3/share if the head to head results vs Sustiva are favorable?

[DewDiligence]

IDIX 2009 Clinical Goals

[Various updates of which the most consequential is the guidance
for a NVS decision by year-end on whether to license IDX184.]


HCV

Mid 2009: Complete IDX184 monotherapy study.

Mid 2009: Start IDX184 phase-2a combination study (SoC ± IDX184).

Mid 2009: File IND for IDX375 non-nucleoside polymerase inhibitor.

Late 2009: File IND for one of the IDX136/IDX316 protease inhibitors.

End 2009: Decision by NVS on whether to license IDX184.


HIV

Timing unknown (it’s up to the GSK-PFE JV): Start IDX899 phase-2 head-to-head trial vs Sustiva.